Needham Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $35
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $41 to $35.
Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $41 to $35.